Vericel Corp reports results for the quarter ended June 30 - Earnings Summary

• Vericel Corp VCEL.OQ reported a quarterly adjusted loss of 1 cent​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -10 cents. The mean expectation of eight analysts for the quarter was for a loss of 3 cents per share. Wall Street expected results to range from -8 cents to -1 cents per share.

• Revenue rose 20.1% to $63.24 million from a year ago; analysts expected $64.49 million.

• Vericel Corp's reported EPS for the quarter was a loss of 1 cent​.

• The company reported a quarterly loss of $553 thousand.

• Vericel Corp shares had fallen by 4.4% this quarter and lost 26.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Vericel Corp is $58.50, about 30.5% above its last closing price of $40.66

This summary was machine generated from LSEG data July 31 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)